Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 earnings results released March 2, 2026: details in Exhibit 99.1.
Xeris Biopharma Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 earnings results released March 2, 2026: details in Exhibit 99.1
- Covers periods ending December 31, 2025 (Q4 and FY2025)
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xeris Biopharma Holdings, Inc. 8-K filings
Get the next XERS 8-K as it lands
Follow XERS for push alerts, or ask the research agent what this filing means.